You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

 

Online download statistics by month:

Online download statistics by month: September 2023 to February 2026

AbstractFullPdf
Sep 2023781783291
Oct 2023863865265
Nov 2023479481209
Dec 2023302306171
Jan 2024230230188
Feb 2024210210151
Mar 2024253255163
Apr 2024212212166
May 2024187189121
Jun 2024200201141
Jul 2024192194145
Aug 2024140141119
Sep 2024167170129
Oct 2024171172210
Nov 2024216220145
Dec 2024237241157
Jan 2025204208131
Feb 2025300302218
Mar 2025302307213
Apr 2025298300146
May 2025225228167
Jun 202526126495
Jul 2025110
Sep 2025111
Feb 2026110
Total643364823742